S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
Log in
NASDAQ:IDYA

IDEAYA Biosciences Stock Forecast, Price & News

$19.81
+0.98 (+5.20 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$16.21
Now: $19.81
$20.10
50-Day Range
$16.34
MA: $18.54
$20.95
52-Week Range
$2.95
Now: $19.81
$21.38
Volume248,300 shs
Average Volume209,237 shs
Market Capitalization$575.88 million
P/E RatioN/A
Dividend YieldN/A
Beta2.11
IDEAYA Biosciences, Inc., an oncology-focused precision medicine company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate is IDE196, a protein kinase C inhibitor that is in Phase 1/2 clinical trial for genetically-defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting MAT2A for solid tumors with MTAP deletions; Pol-theta in tumors with homologous recombination deficiency, including BRCA mutations; PARG in tumors with BRCA2 mutations in base excision repair; and WRN in high microsatellite instability tumors. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase 1/2 study in metastatic uveal melanoma and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

Headlines

Is IDYA A Good Stock To Buy Now?
December 11, 2020 |  finance.yahoo.com
IDEAYA Biosciences (IDYA) Jumps: Stock Rises 8.2%
December 8, 2020 |  finance.yahoo.com
IDEAYA Biosciences Inc.
October 28, 2020 |  barrons.com
IDEAYA Biosciences, Inc. Common Stock (IDYA)
October 22, 2020 |  nasdaq.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IDYA
CUSIPN/A
CIKN/A
Phone(650) 443-6209
Employees58
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.94 per share

Profitability

Net Income$-41,970,000.00

Miscellaneous

Market Cap$575.88 million
Next Earnings Date3/23/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.33 out of 5 stars

Medical Sector

723rd out of 1,968 stocks

Pharmaceutical Preparations Industry

348th out of 771 stocks

Analyst Opinion: 2.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
$19.81
+0.98 (+5.20 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IDYA News and Ratings via Email

Sign-up to receive the latest news and ratings for IDYA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











IDEAYA Biosciences (NASDAQ:IDYA) Frequently Asked Questions

Is IDEAYA Biosciences a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IDEAYA Biosciences in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IDEAYA Biosciences stock.
View analyst ratings for IDEAYA Biosciences
or view top-rated stocks.

What stocks does MarketBeat like better than IDEAYA Biosciences?

Wall Street analysts have given IDEAYA Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but IDEAYA Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is IDEAYA Biosciences' next earnings date?

IDEAYA Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, March 23rd 2021.
View our earnings forecast for IDEAYA Biosciences
.

How were IDEAYA Biosciences' earnings last quarter?

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) posted its quarterly earnings data on Tuesday, November, 17th. The company reported ($0.17) EPS for the quarter, missing analysts' consensus estimates of $2.93 by $3.10. The company earned $8.97 million during the quarter, compared to analyst estimates of $55.83 million.
View IDEAYA Biosciences' earnings history
.

How has IDEAYA Biosciences' stock price been impacted by Coronavirus (COVID-19)?

IDEAYA Biosciences' stock was trading at $4.85 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, IDYA stock has increased by 308.5% and is now trading at $19.81.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for IDYA?

6 equities research analysts have issued 1 year target prices for IDEAYA Biosciences' shares. Their forecasts range from $12.00 to $28.00. On average, they anticipate IDEAYA Biosciences' stock price to reach $22.67 in the next year. This suggests a possible upside of 14.4% from the stock's current price.
View analysts' price targets for IDEAYA Biosciences
or view top-rated stocks among Wall Street analysts.

Who are IDEAYA Biosciences' key executives?

IDEAYA Biosciences' management team includes the following people:
  • Mr. Yujiro S. Hata, Co-Founder, CEO, Pres & Director (Age 47, Pay $622.29k)
  • Mr. Michael P. Dillon, Sr. VP, Chief Scientific Officer & Head of Research (Age 53, Pay $444.57k)
  • Mr. Jeffrey Hager, Co-Founder & Member of the Scientific Advisory Board (Age 57)
  • Mr. Paul A. Stone, Sr. VP, CFO & Principal Accounting Officer (Age 57)
  • Mr. Jason S. Throne J.D., Esq., Sr. VP, Gen. Counsel & Company Sec. (Age 50)
  • Ms. Julie Patel, VP of HR
  • Dr. Mark Lackner Ph.D., Sr. VP and Head of Biology & Translational Sciences (Age 54)
  • Dr. Paul A. Barsanti Ph.D., VP & Head of Drug Discovery

Who are some of IDEAYA Biosciences' key competitors?

What other stocks do shareholders of IDEAYA Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEAYA Biosciences investors own include Aldeyra Therapeutics (ALDX), Fulcrum Therapeutics (FULC), OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), The Boeing (BA), Xeris Pharmaceuticals (XERS), Entasis Therapeutics (ETTX), Livongo Health (LVGO) and NVIDIA (NVDA).

When did IDEAYA Biosciences IPO?

(IDYA) raised $70 million in an initial public offering (IPO) on Thursday, May 23rd 2019. The company issued 5,000,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, Citigroup and Jefferies served as the underwriters for the IPO.

What is IDEAYA Biosciences' stock symbol?

IDEAYA Biosciences trades on the NASDAQ under the ticker symbol "IDYA."

Who are IDEAYA Biosciences' major shareholders?

IDEAYA Biosciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.18%), Federated Hermes Inc. (3.78%), Price T Rowe Associates Inc. MD (1.62%), Northern Trust Corp (0.69%), Renaissance Technologies LLC (0.48%) and Nuveen Asset Management LLC (0.28%). Company insiders that own IDEAYA Biosciences stock include Alexandria Venture Investments, Bvf Partners L P/Il, Jason Throne, Mark Lackner, Michael P Dillon, Paul A Stone, Timothy M Shannon, Value Fund L P Biotechnology and Ventures Iv LP 5Am.
View institutional ownership trends for IDEAYA Biosciences
.

Which institutional investors are selling IDEAYA Biosciences stock?

IDYA stock was sold by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC, and Barclays PLC. Company insiders that have sold IDEAYA Biosciences company stock in the last year include Jason Throne, Mark Lackner, Michael P Dillon, Paul A Stone, and Ventures Iv LP 5Am.
View insider buying and selling activity for IDEAYA Biosciences
or view top insider-selling stocks.

Which institutional investors are buying IDEAYA Biosciences stock?

IDYA stock was bought by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Price T Rowe Associates Inc. MD, BlackRock Inc., JPMorgan Chase & Co., Mission Creek Capital Partners Inc., Hamilton Lane Advisors LLC, Northern Trust Corp, and Wells Fargo & Company MN. Company insiders that have bought IDEAYA Biosciences stock in the last two years include Alexandria Venture Investments, Bvf Partners L P/Il, Paul A Stone, Timothy M Shannon, and Value Fund L P Biotechnology.
View insider buying and selling activity for IDEAYA Biosciences
or or view top insider-buying stocks.

How do I buy shares of IDEAYA Biosciences?

Shares of IDYA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IDEAYA Biosciences' stock price today?

One share of IDYA stock can currently be purchased for approximately $19.81.

How much money does IDEAYA Biosciences make?

IDEAYA Biosciences has a market capitalization of $575.88 million. The company earns $-41,970,000.00 in net income (profit) each year or ($3.36) on an earnings per share basis.

How many employees does IDEAYA Biosciences have?

IDEAYA Biosciences employs 58 workers across the globe.

What is IDEAYA Biosciences' official website?

The official website for IDEAYA Biosciences is www.ideayabio.com.

Where are IDEAYA Biosciences' headquarters?

IDEAYA Biosciences is headquartered at 7000 SHORELINE COURT SUITE 350, SOUTH SAN FRANCISCO CA, 94080.

How can I contact IDEAYA Biosciences?

IDEAYA Biosciences' mailing address is 7000 SHORELINE COURT SUITE 350, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at (650) 443-6209 or via email at [email protected]


This page was last updated on 3/8/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.